it was discovered by scientists at the pfizer research site in sandwich uk under the identifier uk 88 525 and used to be marketed by novartis in 2010 the us rights were sold to warner chilcott for 400 million us ddarifenacin should not be used in people with urinary retention anticholinergic agents such as darifenacin may also produce constipation and blurred vision heat prostration due to decreased sweating can occur when anticholinergics such as darifenacin are used in a hot environment darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence urgency and frequency in adults it may also be recommended with an alpha blocker to help provide symptomatic benefit for overactive bladder and obstructive symptoms such as likely associated with benign prostatic hypertrophy darifenacin works by blocking the m muscarinic acetylcholine receptor which is primarily responsible for bladder muscle contractions it thereby decreases the urgency to urinate it is not known whether this selectivity for the m receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome